Valneva Investor Relations Material

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. The company’s core strengths are in bacterial vaccines and immunotherapeutic vaccines against cancers, based on its innovative and proprietary technology platforms, including well-established cell line and antigenic know-how. Products in advanced clinical development are a vaccine against Lyme disease (Phase III), a first-in-class vaccine candidate against Clostridium difficile infection (Phase II) and a conjugate vaccine targeting Pseudomonas aeruginosa illness in patients suffering from cystic fibrosis (Phase I). Vaccines under preclinical development include recombinant solutions against tetanus and diphtheria, pertussis and invasive meningococcal diseases. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the US with approximately 550 employees."